MAS
IONS icon

Meeder Advisory Services’s Ionis Pharmaceuticals IONS Stock Holding History

Meeder Advisory Services’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$544K Buy
7,239
+83
+1% +$6.55K 0.02% 377
2025
Q4 		$566K Buy
7,156
+386
+6% +$29.1K 0.02% 375
2025
Q3 		$443K Buy
6,770
+126
+2% +$6.15K 0.02% 416
2025
Q2 		$263K Buy
+6,644
New +$217K 0.01% 511

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Meeder Advisory Services's IONS Position: Q1 2026 in Review

Meeder Advisory Services increased its Ionis Pharmaceuticals (IONS) stake by 1.2% in Q1 2026, buying an estimated $6.55K and bringing the position to 7,239 shares worth $544K. The position accounts for 0.02% of the portfolio, ranked #377.

Meeder Advisory Services first reported a position in IONS in Q2 2025 and has held it in 4 quarters since. The position peaked at $566K in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Meeder Advisory Services held 7,239 shares of Ionis Pharmaceuticals worth $544K as of Q1 2026.
  • Meeder Advisory Services bought 83 Ionis Pharmaceuticals shares in Q1 2026, an estimated $6.55K.
  • Ionis Pharmaceuticals made up 0.02% of Meeder Advisory Services's portfolio in Q1 2026, its #377 holding.
  • Meeder Advisory Services first reported a position in Ionis Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Meeder Advisory Services's Ionis Pharmaceuticals position peaked at $566K in Q4 2025.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Meeder Advisory Services's 13F filing for Q1 2026, filed 7 May 2026.